Watch IDEXX Laboratories'
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on IDEXX with seven of 11 analysts rating it hold. Analysts don't like IDEXX much as competitor Henry Schein overall. Seven out of 13 analysts rate Henry Schein a buy compared to four of 11 for IDEXX. Analysts still rate the stock a hold, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $294.9 million in revenue this quarter. That would represent a rise of 9.4% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.64 per share. Estimates range from $0.63 to $0.66.
What our community says:
CAPS All-Stars are solidly backing the stock with 98.5% awarding it an "outperform" rating. The community at large backs the All-Stars with 95.1% assigning it a rating of "outperform." Fools are keen on IDEXX, though the message boards have been quiet lately with only 70 posts in the past 30 days. IDEXX has a bullish CAPS rating of five out of five stars that is about on par with the Fool community assessment.
IDEXX Laboratories' profit has risen year over year by an average of 17.3% over the past five quarters. Revenue has now gone up for three straight quarters.
For all our IDEXX Laboratories-specific analysis, including earnings and beyond, add IDEXX Laboratories to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.